Patients with equivocal results and no other definitive IgH or IgL-λ translocation
| Abnormalities . | . | Δ13% . | Aneuploidy (%) . | VH/CH (%) . | Fusion signals (%) . | Heavy chain . | Light chain . | BM plasmacytosis, PCLI (%) . | κ/λ ratio . |
|---|---|---|---|---|---|---|---|---|---|
| Equivocal translocations with possible partner identified | |||||||||
| Equivocal | t(11;14) | ND | 100 | 20 | 17 | γ | κ | 5.0 | 99:1 |
| Equivocal | t(11;14) | 16 | 80 | 16 | 10 | γ | κ | 1.3 | 4:1 |
| Equivocal | t(11;14) | 88 | 71 | 17 | 10 | γ | λ | 3.0 | 1:4 |
| Equivocal | t(11;14) | ND | 96 | 19 | 17 | γ | κ | 5.1 | 99:1 |
| Equivocal | t(11;14) | ND | 56 | 13 | 11 | α | λ | 3.0 | 1:99 |
| Equivocal | t(11;14) | 82 | 100 | 17 | 11 | γ | κ | 1.0 | 5:1 |
| Equivocal | t(4;14) | ND | 80 | 22 | 19 | γ | λ | TFTC | TFTC |
| Equivocal translocations without possible partner identified | |||||||||
| Equivocal | 14q32+ | ND | 22 | NA | γ | λ | 0.7 | 2:1 | |
| Equivocal | 14q32+ | 19 | 76 | 17 | NA | α | κ | 1.0 | 5:1 |
| Equivocal | 14q32+ | ND | 14 | NA | γ | κ | 3.0 | 15:1 | |
| Equivocal | 14q32+ | ND | 10 | NA | γ | κ | 2.0 | 99:1 | |
| Equivocal | 14q32+ | 2 | 16 | NA | γ | λ | 4.0 | 1:1 | |
| Equivocal | 14q32+ | 5 | 11 | 13 | NA | γ | κ | 3.0 | 2:1 |
| Equivocal | 14q32+ | 5 | 12 | NA | γ | κ | 1.0 | 2:1 | |
| Equivocal | IgL-λ | 8 | 17 | NA | γ | κ | 1.5 | 6:1 | |
| Equivocal | IgL-λ | 25 | 18 | NA | ND | κ | 2.7 | 99:1 | |
| Equivocal | IgL-λ | ND | 18 | NA | γ | λ | 1.0 | 1:1 | |
| Abnormalities . | . | Δ13% . | Aneuploidy (%) . | VH/CH (%) . | Fusion signals (%) . | Heavy chain . | Light chain . | BM plasmacytosis, PCLI (%) . | κ/λ ratio . |
|---|---|---|---|---|---|---|---|---|---|
| Equivocal translocations with possible partner identified | |||||||||
| Equivocal | t(11;14) | ND | 100 | 20 | 17 | γ | κ | 5.0 | 99:1 |
| Equivocal | t(11;14) | 16 | 80 | 16 | 10 | γ | κ | 1.3 | 4:1 |
| Equivocal | t(11;14) | 88 | 71 | 17 | 10 | γ | λ | 3.0 | 1:4 |
| Equivocal | t(11;14) | ND | 96 | 19 | 17 | γ | κ | 5.1 | 99:1 |
| Equivocal | t(11;14) | ND | 56 | 13 | 11 | α | λ | 3.0 | 1:99 |
| Equivocal | t(11;14) | 82 | 100 | 17 | 11 | γ | κ | 1.0 | 5:1 |
| Equivocal | t(4;14) | ND | 80 | 22 | 19 | γ | λ | TFTC | TFTC |
| Equivocal translocations without possible partner identified | |||||||||
| Equivocal | 14q32+ | ND | 22 | NA | γ | λ | 0.7 | 2:1 | |
| Equivocal | 14q32+ | 19 | 76 | 17 | NA | α | κ | 1.0 | 5:1 |
| Equivocal | 14q32+ | ND | 14 | NA | γ | κ | 3.0 | 15:1 | |
| Equivocal | 14q32+ | ND | 10 | NA | γ | κ | 2.0 | 99:1 | |
| Equivocal | 14q32+ | 2 | 16 | NA | γ | λ | 4.0 | 1:1 | |
| Equivocal | 14q32+ | 5 | 11 | 13 | NA | γ | κ | 3.0 | 2:1 |
| Equivocal | 14q32+ | 5 | 12 | NA | γ | κ | 1.0 | 2:1 | |
| Equivocal | IgL-λ | 8 | 17 | NA | γ | κ | 1.5 | 6:1 | |
| Equivocal | IgL-λ | 25 | 18 | NA | ND | κ | 2.7 | 99:1 | |
| Equivocal | IgL-λ | ND | 18 | NA | γ | λ | 1.0 | 1:1 | |
ND indicates not done; TFTC, too few cells to count; NA, not applicable.